The general results of this study show the clinical utility of serum MCP-1 and uMCP-1/Cr in CanL to detect systemic inflammation and renal damage with the first marker and, renal inflammation and damage with the second, even if uMCP-1/Cr appears to be a better marker to identify renal damage compared with serum MCP-1. This evidence concerns the gene CCL2 and inflammatory response.